Overview

Second STOP After Pioglitazone Priming in CML Patients

Status:
Recruiting

Trial end date:
2021-12-01

Target enrollment:

Participant gender:

Summary

Single-center study, prospective, phase II trial. The study objectives are : - To assess safety and pharmacokinetics of the combination of PIO and TKI in CML subjects who experience a loss of MMR following a first TKI discontinuation. - To assess survival without loss of MMR over a 12 months period following a second TKI discontinuation in subjects who achieve or maintain < MR4.5 with the combination PIO and TKI administered for at least 6 months.

Phase:

Phase 2

Details

Lead Sponsor:

Versailles Hospital

Collaborator:

Pr Philippe ROUSSELOT

Treatments:

Pioglitazone